OPKO Health (OPK) Set to Announce Quarterly Earnings on Tuesday

OPKO Health (NASDAQ:OPK) is set to announce its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). The company had revenue of $181.90 million during the quarter, compared to analyst estimates of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.11) earnings per share. On average, analysts expect OPKO Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OPKO Health Price Performance

OPK opened at $1.30 on Friday. OPKO Health has a twelve month low of $0.85 and a twelve month high of $2.24. The company’s 50-day moving average price is $1.13 and its two-hundred day moving average price is $1.22. The stock has a market cap of $906.09 million, a price-to-earnings ratio of -5.20 and a beta of 1.81. The company has a quick ratio of 1.22, a current ratio of 1.55 and a debt-to-equity ratio of 0.15.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $5.00 price objective on shares of OPKO Health in a research note on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Wednesday, April 3rd. Barrington Research reiterated an “outperform” rating and issued a $1.50 target price on shares of OPKO Health in a research note on Monday, April 1st. Finally, StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Friday, March 1st.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 500,000 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were acquired at an average cost of $0.87 per share, for a total transaction of $435,000.00. Following the purchase, the chief executive officer now directly owns 210,968,225 shares of the company’s stock, valued at $183,542,355.75. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders bought 4,600,000 shares of company stock worth $4,393,000 in the last three months. Corporate insiders own 47.26% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.